|
|
|
| Efficacy Evaluation of Transradial Approach PCI Combined With Tirofiban in The Treatment of Patients With Acute ST-Segment Elevation Myocardial Infarction |
| Li Xiuhua |
| Department of Cardiovascular Medicine,No.990 Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army（Xinyang District）,Xinyang 464000,China |
|
|
|
|
Abstract Objective To explore the efficacy of transradial approach（TRA）percutaneous coronary intervention（PCI）combined with tirofiban in the treatment of patients with acute ST-segment elevation myocardial infarction（ASTEMI）. Methods 84 patients with ASTEMI were selected and divided into groups according to different treatment plans,with 42 cases in each group.The control group was treated with TRA-PCI,and the observation group was treated with TRA-PCI combined with tirofiban.The coronary angiography measurementresultsbefore and after surgery,serum troponin I（cTnI）and creatine kinase mixed isoenzyme（CK-MB）levels before and 24 hours after surgery,cardiac function indexes 1 week after surgery,and the incidence of bleeding and thrombocytopenia were compared. Results The acquisition rate of TIMI myocardial perfusion grade（TMPG）level 3 in the observation groupafter surgery was higher than that in the control group（P<0.05）;The serum cTnI and CK-MB levels in the observation group at 24 hour after surgerywere lower than those in the control group（P<0.05）;One weekafter surgery,the left ventricular ejection fraction（LVEF）of the observation group was higher than that of the control group（P<0.05）;The thrombocytopenia was not found in the two groups,and there was no significant difference in the incidence of bleeding between the two groups（P>0.05）. Conclusion The treatment of ASTEMI patients with TRA-PCI combined with tirofiban can improve postoperative myocardial tissue perfusion, reduce the level of postoperativeserum myocardial biochemical markers after surger,improve cardiac function,and has high safety.
|
|
Received: 04 June 2021
|
|
|
|
|
|
[1] 刘杰,宋书凯.早期应用不同剂量替罗非班在急性ST段抬高型心肌梗死患者中的临床观察[J].天津医科大学学报,2017,23(1):59-62.
[2] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393.
[3] 赵纯华. 依替巴肽与替罗非班在急性ST段抬高型心肌梗死病人PCI治疗中的疗效及安全性对比研究[J].中西医结合心脑血管病杂志,2017,15(19):2434-2437.
[4] 段小春,曾玉杰,刘梅颜,等.替罗非班对急性ST段抬高型心肌梗死患者血小板抑制率的影响及安全性评价[J].中国循证心血管医学杂志,2019,11(6):739-741.
[5] 周召锋,施亚明,王斌,等.替格瑞洛联合冠状动脉内注射替罗非班对STEMI急诊PCI后心肌灌注和预后的影响[J].江苏医药,2017,43(11):790-793.
[6] 廖开历,蓝璧高.尼可地尔联合替罗非班对老年ST段抬高型心肌梗死患者经皮冠状动脉介入术术后即刻心肌血流灌注和预后的影响[J].广西医学,2019,41(23):3005-3008. |
| [1] |
. [J]. journal1, 2021, 41(1): 72-73. |
|
|
|
|
2022, Vol. 42 
